Use of beta 2 agonists in asthma: much ado about nothing? Adverse effects are not proved.
作者信息
Fuller R W
机构信息
Glaxo Group Research and Development Limited, Middlesex.
出版信息
BMJ. 1994 Sep 24;309(6957):795-6. doi: 10.1136/bmj.309.6957.795.
Abstract
摘要
相似文献
1
Use of beta 2 agonists in asthma: much ado about nothing? Adverse effects are not proved.β2 激动剂在哮喘治疗中的应用：小题大做？尚未证实存在不良反应。
BMJ. 1994 Sep 24;309(6957):795-6. doi: 10.1136/bmj.309.6957.795.
2
Use of beta 2 agonists in asthma: much ado about nothing? Still cause for concern.β2 激动剂在哮喘治疗中的应用：小题大做？仍值得关注。
BMJ. 1994 Sep 24;309(6957):794-5. doi: 10.1136/bmj.309.6957.794.
3
Asthma and the beta 2-agonist controversy: much ado about something.哮喘与β2受体激动剂之争：小题大做。
Del Med J. 1995 Dec;67(12):624-8.
4
Adding LABAs to inhaled glucocorticoids for asthma.将长效β2受体激动剂添加到吸入性糖皮质激素中用于治疗哮喘。
N Engl J Med. 2011 Sep 29;365(13):1260-1; author reply 1261. doi: 10.1056/NEJMc1108965.
5
Beta-2 adrenergic agonists: focus on safety and benefits versus risks.β2 肾上腺素能激动剂：关注安全性和益处与风险的关系。
Curr Opin Pharmacol. 2010 Jun;10(3):246-53. doi: 10.1016/j.coph.2010.04.009. Epub 2010 May 6.
6
Part IV: Genetic variations in beta2-adrenergic receptors: long-acting and short-acting beta2-agonists and therapeutic response.第四部分：β2 肾上腺素能受体的基因变异：长效和短效β2 激动剂与治疗反应
Curr Med Res Opin. 2007 Sep;23 Suppl 3:S29-36. doi: 10.1185/030079907.
7
Is there a problem with inhaled long-acting beta-adrenergic agonists?吸入长效β-肾上腺素能激动剂存在问题吗？
J Allergy Clin Immunol. 2006 Jan;117(1):3-16; quiz 17. doi: 10.1016/j.jaci.2005.10.013.
8
An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids.吸入皮质类固醇治疗哮喘患者中长效β-激动剂的安全性更新。
Expert Opin Drug Saf. 2010 May;9(3):407-19. doi: 10.1517/14740330903535852.
9
Mechanisms of adverse effects of {beta}-agonists in asthma.β-激动剂在哮喘中的不良反应机制。
Thorax. 2009 Sep;64(9):739-41. doi: 10.1136/thx.2009.119230.
10
[Asthma overmortality under beta-2-mimetics. Does it depend on the drug itself or on false use].
MMW Fortschr Med. 2005 Mar 10;147(10):16.
本文引用的文献
1
Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.哮喘中常规吸入β受体激动剂：对病情加重和肺功能的影响。
Thorax. 1993 Feb;48(2):134-8. doi: 10.1136/thx.48.2.134.
2
3
Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.施立稳全国性监测研究：沙美特罗与沙丁胺醇在需要常规支气管扩张剂治疗的哮喘患者中的比较
BMJ. 1993 Apr 17;306(6884):1034-7. doi: 10.1136/bmj.306.6884.1034.
4
Observations on recent increase in mortality from asthma.关于近期哮喘死亡率上升的观察
Br Med J. 1968 Feb 10;1(5588):335-9. doi: 10.1136/bmj.1.5588.335.
5
A century of asthma deaths in young people.年轻人哮喘死亡的一个世纪情况。
Br Med J. 1968 Jul 27;3(5612):245-6. doi: 10.1136/bmj.3.5612.245.
6
Minimization: a new method of assigning patients to treatment and control groups.最小化法：一种将患者分配到治疗组和对照组的新方法。
Clin Pharmacol Ther. 1974 May;15(5):443-53. doi: 10.1002/cpt1974155443.
7
Regular inhaled beta-agonist treatment in bronchial asthma.支气管哮喘的常规吸入β-激动剂治疗
Lancet. 1990 Dec 8;336(8728):1391-6. doi: 10.1016/0140-6736(90)93098-a.
8
A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group.沙美特罗与沙丁胺醇对哮喘患者的十二个月比较。欧洲研究小组。
Eur Respir J. 1992 Oct;5(9):1062-7.
9
A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.沙美特罗与沙丁胺醇治疗轻至中度哮喘的比较。
N Engl J Med. 1992 Nov 12;327(20):1420-5. doi: 10.1056/NEJM199211123272004.
10
The use of beta-agonists and the risk of death and near death from asthma.β-激动剂的使用与哮喘导致的死亡及濒死风险
N Engl J Med. 1992 Feb 20;326(8):501-6. doi: 10.1056/NEJM199202203260801.
Zotero 插件